Daniel Vitt

Grafelfing, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.

Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.

Journal: Expert opinion on investigational drugs

Published: July 16, 2026

DHODH Inhibitors Based on the Vidofludimus Scaffold Containing Carboxylic Acid Bioisosteres Exert a Superior Broad-Spectrum Antiviral Activity.

DHODH Inhibitors Based on the Vidofludimus Scaffold Containing Carboxylic Acid Bioisosteres Exert a Superior Broad-Spectrum Antiviral Activity.

Journal: Journal of medicinal chemistry

Published: June 03, 2026

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress Sensitivity.

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress Sensitivity.

Journal: bioRxiv : the preprint server for biology

Published: April 27, 2026

Development of a Brain-Penetrant Nurr1 Agonist Tool.

Development of a Brain-Penetrant Nurr1 Agonist Tool.

Journal: ChemMedChem

Published: January 08, 2026

Carboxylic Acid Bioisosteres Boost Nurr1 Agonist Selectivity.

Carboxylic Acid Bioisosteres Boost Nurr1 Agonist Selectivity.

Journal: Journal of medicinal chemistry

Published: July 17, 2025

Selective disruption of RORγt-CBFβ interaction by IMU-935 prevents RORγt-dependent Th17 autoimmunity but not thymocyte development.

Selective disruption of RORγt-CBFβ interaction by IMU-935 prevents RORγt-dependent Th17 autoimmunity but not thymocyte development.

Journal: The Journal of clinical investigation

Published: August 12, 2024

Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity.

Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity.

Journal: Antiviral research

Published: July 19, 2024

Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.

Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.

Journal: Clinical and translational gastroenterology

Published: July 15, 2024

Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.

Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 25, 2024

Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity.

Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity.

Journal: ChemMedChem

Published: April 22, 2024

Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: April 08, 2024

Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels.

Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels.

Journal: Antiviral research

Published: August 12, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026